TAKAESU YOSHIKAZU

写真a

Title

Associate Professor

Researcher Number(JSPS Kakenhi)

90421015
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Associate Professor  

To the head of this page.▲

University 【 display / non-display 】

  • 　
    -
    2004.03

    Tokyo Medical University   Faculty of Medicine   Graduated

To the head of this page.▲

External Career 【 display / non-display 】

  • 2013.10
    -
    2017.12

    Tokyo Medical University  

  • 2018.01
    　
    　

    Kyorin University  

  • 2021.01
    　
    　

    University of the Ryukyus  

To the head of this page.▲

Affiliated academic organizations 【 display / non-display 】

  • 　
    　
    　
     

    The Japanese Society of Psychiatry and Neurology 

  • 　
    　
    　
     

    THE JAPANESE SOCIETY OF NEUROPSYCHOPHARMACOLOGY 

  • 　
    　
    　
     

    JAPANESE SOCIETY OF BIOLOGICAL PSYCHIATRY 

  • 　
    　
    　
     

    Japanese Society of Mood Disorders 

To the head of this page.▲

Research Interests 【 display / non-display 】

  • sleep medicine

  • circadian rhythm

  • bipolar disorder

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life Science / Psychiatry

To the head of this page.▲

Acquisition of a qualification 【 display / non-display 】

  • Doctor

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia.

    Aoki Y, Takaesu Y, Matsui K, Tokumasu T, Tani H, Takekita Y, Kanazawa T, Kishimoto T, Tarutani S, Hashimoto N, Takeuchi H, Mishima K, Inada K

    Neuropsychopharmacology reports ( Neuropsychopharmacology Reports )    2023.07 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    AIM: Continued antipsychotic treatment is the key to preventing relapse. Maintenance antipsychotic monotherapy and optimal dose use are recommended for individuals with stable schizophrenia because of their undesirable effects. Decision aids (DAs) are clinical conversation tools that facilitate shared decision-making (SDM) between patients and health-care providers. This study aimed to describe the development process and results of acceptability testing of a DA for individuals with stable schizophrenia, considering (i) whether to continue high-dose antipsychotics or reduce to the standard dose and (ii) whether to continue two antipsychotics or shift to monotherapy. METHODS: A DA was developed according to the guidelines for the appropriate use of psychotropic medications and International Patient Decision Aid Standards (IPDAS). First, a DA prototype was developed based on a previous systematic review and meta-analysis conducted for identifying the effects of continuing or reducing antipsychotic treatment. Second, mixed-method survey was performed among individuals with schizophrenia and health-care providers to modify and finalize the DA. RESULTS: The DA consisted of an explanation of schizophrenia, options to continue high-dose antipsychotics or reduce to the standard dose, options to continue two antipsychotics or shift to monotherapy, pros and cons of each option, and a value-clarification worksheet for each option. The patients (n = 20) reported acceptable language use (75%), adequate information (75%), and well-balanced presentation (79%). Health-care providers (n = 20) also provided favorable overall feedback. The final DA covered six IPDAS qualifying criteria. CONCLUSION: A DA was successfully developed for schizophrenia, considering whether to reduce antipsychotics, which can be used in the SDM process.

  • Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.

    Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga JI, Yasui-Furukori N, Yamada N, Hori H, Muraoka H, Ohi K, Ogasawara K, Shinichiro O, Takeshima M, Ichihashi K, Fukumoto K, Iida H, Yamada H, Furihata R, Makinodan M, Takaesu Y, Numata S, Komatsu H, Hishimoto A, Kido M, Atake K, Yamagata H, Kikuchi S, Hashimoto N, Usami M, Katsumoto E, Asami T, Kubota C, Matsumoto J, Miura K, Hirano Y, Watanabe K, Inada K, Hashimoto R

    Journal of clinical psychopharmacology     2023.05 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics.

    Takeshima M, Yoshizawa K, Enomoto M, Ogasawara M, Kudo M, Itoh Y, Ayabe N, Takaesu Y, Mishima K

    Psychiatry and clinical neurosciences ( Psychiatry and Clinical Neurosciences )  77 ( 5 ) 264 - 272   2023.05 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    AIM: This study aimed to examine the effect of Japanese policies for appropriate hypnotics use and novel hypnotics (e.g., melatonin receptor agonist [MRA] and orexin receptor antagonist [ORA]) on long-term prescriptions of hypnotics. METHODS: This retrospective study was conducted using a large-scale health insurance claims database. Among subscribers prescribed hypnotics at least once between April 2005 and March 2021, those prescribed hypnotics for the first time after being included in the database in three periods (period 1, April 2012-March 2013; period 2, April 2016-March 2017; and period 3, April 2018-March 2019) were eligible. These were set considering the timing of the 2014 and 2018 medical fee revisions (2014 for polypharmacy of three or more hypnotics, 2018 for long-term prescription of benzodiazepine receptor agonists for >12 months). The duration of consecutive prescriptions of hypnotics over 12 months was evaluated. Factors associated with short-term prescriptions of hypnotics were also investigated. RESULTS: In total, 186,535 participants were newly prescribed hypnotics. The mean duration of prescriptions was 2.9 months, and 9.3% of participants were prescribed hypnotics for 12 months. Prescription periods were not associated with short-term prescriptions of hypnotics. ORA use was associated with short-term prescriptions of hypnotics (adjusted hazard ratio, 1.077; 95% confidence interval, 1.035-1.120; p<0.001), but MRA use was not. CONCLUSION: Japanese policies had no statistically significant effect on long-term prescriptions of hypnotics. Although this study suggests initiating ORA for insomniacs as a candidate strategy to prevent long-term prescriptions of hypnotics, further research is necessary to draw conclusions. This article is protected by copyright. All rights reserved.

  • A Comparison between Perceptions of Psychiatric Outpatients and Psychiatrists Regarding Benzodiazepine Use and Decision Making for Its Discontinuation: A Cross-Sectional Survey in Japan.

    Aoki Y, Takeshima M, Tsuboi T, Katsumoto E, Udagawa K, Inada K, Watanabe K, Mishima K, Takaesu Y

    International journal of environmental research and public health ( International Journal of Environmental Research and Public Health )  20 ( 7 ) 5373 - 5373   2023.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    Background: Although long-term use of benzodiazepines and z-drugs (BZDs) is not recommended, little is known about the stakeholders’ perceptions. This study aimed to assess and compare the perceptions of BZD use and decision making regarding its discontinuation between psychiatric outpatients and psychiatrists. Methods: A cross-sectional survey was conducted. Results: Of 104 outpatients, 92% were taking hypnotics and 96% were taking anxiolytics for ≥a year, while 49% were willing to taper hypnotic/anxiolytics within a year of starting. Most psychiatrists felt that “patient and psychiatrist make the decision together on an equal basis” compared to patients (p &lt; 0.001), while more patients felt that “the decision is (was) made considering the psychiatrists’ opinion” compared to psychiatrists (p &lt; 0.001). Of 543 psychiatrists, 79% reported “patients were not willing to discontinue hypnotic/anxiolytic” whereas a certain number of patients conveyed “psychiatrists did not explain in enough detail about hypnotic/anxiolytic discontinuation such as procedure (18.3%), timing (19.2%), and appropriate condition (14.4%)”. Conclusion: The results suggest that the majority of psychiatric outpatients were taking hypnotic/anxiolytics for a long time against their will. There might be a difference in perceptions toward hypnotic/anxiolytic use and decision making for its discontinuation between psychiatric outpatients and psychiatrists. Further research is necessary to fill this gap.

  • Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial

    Takaesu Y.

    Clinical and Translational Science ( Clinical and Translational Science )  16 ( 4 ) 581 - 592   2023.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

display all >>

To the head of this page.▲

Other Papers 【 display / non-display 】

  • A retrospective multicenter analysis of factors related to the achievement of discontinuation of anticholinergic medication in patients with schizophrenia

    村田篤信, 古郡規雄, 堀輝, 長谷川尚美, 姜善貴, 高江洲義和, 伊賀淳一, 越智紳一郎, 降籏隆二, 鬼塚俊明, 竹島正浩, 三浦健一郎, 松本純弥, 稲田健, 渡邊衡一郎, 橋本亮太

    日本臨床精神神経薬理学会プログラム・抄録集   30th   2021

     

    J-GLOBAL

  • 睡眠-覚醒リズム障害を訴える患者

      108 ( 12 ) 1579 - 1582   2020.12

     

    DOI

  • 共同意思決定(SDM)の普及可能性

      62 ( 10 ) 1387 - 1392   2020.10

     

    DOI

  • Treatment strategy for treatment refactory depression focusing on sleep disturbances.

    Yoshikazu Takaesu

    Journal of Clinical and Experimental Medicine (IGAKU NO AYUMI)   272 ( 5 ) 429 - 432   2020.02

     

  • Combination therapy with two sleeping drugs for insomnia

    Yuta Kanda, Yoshikazu Takaesu

    Japanese journal of clinical psychopharmacology   22 ( 7 ) 719 - 725   2019.07

     

display all >>

To the head of this page.▲

Academic Awards 【 display / non-display 】

  • Excellent Presentation Award

    2016    

    Winner: Yoshikazu Takaesu

  • Clinical Research Award

    2016   American Academy of Dental Sleep Medicine  

    Winner: Yoshikazu Takaesu

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

  • Grant-in-Aid for Scientific Research(B)

    Project Year: 2023.04  -  2027.03 

    Direct: 12,300,000 (YEN)  Overheads: 15,990,000 (YEN)  Total: 3,690,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2023.04  -  2027.03 

    Direct: 3,500,000 (YEN)  Overheads: 4,550,000 (YEN)  Total: 1,050,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2023.04  -  2026.03 

    Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

  • Investigation of the prediction and prevention of relapse using multidisciplinary team medicine in the treatment of refractory depression.

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -  2024.03 

    Direct: 1,500,000 (YEN)  Overheads: 1,950,000 (YEN)  Total: 3,450,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -  2023.03 

    Direct: 3,400,000 (YEN)  Overheads: 4,420,000 (YEN)  Total: 1,020,000 (YEN)

display all >>

To the head of this page.▲